High-Dose Contact RT Feasible in KS on the Hard Palate

Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

CHICAGO--In feasibility testing, a custom-designed high-dose-rate contact radiation therapy technique destroyed Kaposi's sarcoma on the hard palate in less time than conventional external beam radiotherapy and with less severe side effects.

CHICAGO--In feasibility testing, a custom-designed high-dose-rate contactradiation therapy technique destroyed Kaposi's sarcoma on the hard palatein less time than conventional external beam radiotherapy and with lesssevere side effects.

The technique was developed at New York Hospital and Cornell UniversityMedical Center by Drs. James Wong, Lourdes Nisce, and Dattareyudu Nori.

Dr. Wong, director of Radiation Oncology Research, described the newtechnique at the annual meeting of the Radiological Society of North America(RSNA).

Kaposi's sarcoma of the hard palate, a common presentation in individualswith AIDS, usually is treated by external beam radiotherapy. Despite receivingdoses as low as 180 cGy to 200 cGy per fraction for a maximum dosage of2,600 cGy, AIDS patients who undergo external beam radiotherapy often suffersevere mucositis and xerostomia secondary to their decreased toleranceto radiation.

By concentrating radiation on the tumor itself, the oral high-dose-ratecontact therapy minimizes these adverse side effects while raising radiationdose, Dr. Wong said.

This new form of therapy is delivered by means of a flexible surfaceapplicator that has been shielded with lead on the underside and alongthe lateral edges, in order to protect the tongue, buccal mucosa, and parotidgland from exposure to radiation.

Patient Bites Down on Device

Afterloading source tubes that will deliver the radiation are embeddedin bolus material, which is attached to the applicators and secured inplace with thermoplastic. The applicators are placed in a patient's mouthwhile the thermoplastic is still warm so that the patient can bite downon the device and push the bolus material up against the Kaposi's sarcomalesion on the palate.

Radiation using a high-activity iridium-192 source is administered throughthe afterloading source tubes, which are positioned so that the centerof the radiation source is 0.5 cm from the mucosal surface.

A mean dose of 400 cGy per fraction is administered twice a week fora total initial treatment dose of 1,600 cGy. "Sometimes at the endof treatment, we may not see complete response after this regimen. We waitanother two to four weeks, and usually the tumor disappears. If it doesn't,we give another course of 1,600 cGy," Dr. Wong explained.

Treatment Takes 20 Minutes

Treatment with the oral high-dose-rate contact technique is quick; ittakes only five minutes to prepare the device and 15 minutes to administerthe radiation therapy.

The new contact treatment causes minimal damage to normal tissue. Dr.Wong has calculated that Kapo-si's sarcoma at the contact surface receivesthe full dosage of radiation, but because of the lead shielding beneathand at the sides of the device, the tongue receives only 22% of the maximumdosage; the nearest portion of buccal mucosa receives 35% of the maximumdosage; buccal mucosa further away from the contact region receives lessthan 10% of the dosage; and the parotid gland receives 8% to 11%.

As a result, patients treated with this novel device experience no changesin taste, have only minor mucositis and xerostomia, and require no analgesics,narcotics, or special diets following treatment, he said.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.